HBM contact: Dr Ivo Staijen
Company status: public
Therapeutics develops novel therapeutics that reduce severe side effects of
radiation therapy in cancer patients. The lead molecule GC4419 has demonstrated
efficacy in a phase IIb study in patients with head and neck cancer and has
been granted Fast Track and Breakthrough Therapy designations by the U.S. FDA.